All payments made in the preview are in test mode. Read more
Preview
Regulation

FDA clears MiniMed Fit tubeless insulin pump

The company plans a phased US launch in spring 2027 following clearance for users aged seven and older.

MedTechPost.com Newsroom
FDA clears MiniMed Fit tubeless insulin pump
Illustration: AI-generated

MiniMed has announced FDA clearance for MiniMed Fit, its first tubeless insulin pump. According to the announcement, it is cleared for people with type 1 and type 2 diabetes aged seven and older.

The manufacturer describes up to seven days of wear and a 300-unit reservoir. A compatible iOS or Android app controls the system, while SmartGuard provides automated insulin delivery. At commercial launch, users are expected to have a choice of Simplera Sync or Abbott’s Instinct sensor. A phased US rollout is planned for spring 2027.

Context and evidence

Clearance and launch are not the same event. The company describes manufacturing readiness and planned pharmacy distribution, not broad current availability. Real-world SmartGuard results cited in the source relate to that technology and should not automatically be interpreted as a standalone comparative trial of the new pump.

What it means

The clearance expands the planned choice of automated insulin delivery systems. Availability, compatibility and individual medical suitability still govern actual use; this news is not a treatment recommendation.

Primary source: Original announcement. This report is based on company statements, not an independent clinical assessment.

Author
MedTechPost.com Newsroom
Source-based medical technology reporting with AI assistance and clear editorial context.

More from Regulation